Previous close | 0.0600 |
Open | 0.0100 |
Bid | 0.0000 |
Ask | 1.9900 |
Strike | 375.00 |
Expiry date | 2024-06-21 |
Day's range | 0.0100 - 0.0600 |
Contract range | N/A |
Volume | |
Open interest | 27 |
Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) has approved BLINCYTO® (blinatumomab) for the treatment of adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase, regardless of measurable residual disease (MRD) status.
The latest trading day saw Amgen (AMGN) settling at $298.50, representing a -0.86% change from its previous close.
Viridian (VRDN) intends to initiate two late-stage studies on its experimental thyroid eye disease drug this August. Top-line data from both studies are expected in first-half 2026